Jacques-Olivier Bay

Adjunction of a fish oil emulsion to cytarabine and daunorubicin induction chemotherapy in high-risk AML

M. Béné, J. Bay, C. Récher, 2020, Scientific Reports.

Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial

K. Tarte, R. Houot, O. Casasnovas, 2023, Nature Medicine.

Reduced-intensity versus reduced-toxicity myeloablative fludarabine/busulfan-based conditioning regimens for allografted non-Hodgkin lymphoma adult patients: a retrospective study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire

M. Labopin, P. Chevallier, I. Yakoub-Agha, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Reduced-intensity and non-myeloablative allogeneic stem cell transplantation from alternative HLA-mismatched donors for Hodgkin lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular Therapy

I. Yakoub-Agha, D. Blaise, J. Bay, 2017, Bone Marrow Transplantation.

Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation

D. Blaise, M. Mohty, D. Coso, 2004, Bone Marrow Transplantation.